Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 19, Number 10—October 2013

Dispatch

Hepatitis E Virus among Persons Who Inject Drugs, San Diego, California, USA, 2009–2010

Reena MahajanComments to Author , Melissa G. Collier, Saleem Kamili, Jan Drobeniuc, Jazmine Cuevas-Mota, Richard S. Garfein, and Eyasu Teshale
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (R. Mahajan, M.G. Collier, S. Kamili, J. Drobeniuc, E. Teshale); University of California School of Medicine, San Diego, California, USA (J. Cuevas-Mota, R.S. Garfein)

Main Article

Table

Prevalence of IgG against hepatitis E virus among persons who inject drugs, San Diego, California, USA, 2010*

Characteristic Positive for IgG against HEV, n = 14 Negative for antibody against HEV, n = 494† p value
Sex
M 11 (79) 357 (72) 0.707
F 3 (21) 137 (28) ND
Mean age, y (95% CI) 33.4 (30.1–36.6) 28.5 (27.9–29.0) <0.003
Age ≥30 y 9 (64) 170 (34) 0.013
Race 0.776
White 8 (57) 272 (55) ND
Black 2 (14) 34 (7) ND
Hispanic 2 (14) 137 (28) ND
Other 1 (7) 15 (3) ND
Homeless 11 (79) 287 (58) 0.326
History of incarceration 12 (86) 376 (76) 0.263
Sharing any drug injecting equipment 8 (57) 354 (72) 0.587
Diagnosis of sexually transmitted infection† 1 (7) 93 (19) 0.443
Exchange of sex for money 5 (36) 142 (29) 0.308
Travel to Mexico 10 (71) 314 (64) 0.373
Antibody against HAV 3 (21) 190 (38) 0.504
Antibody against HBc 3 (21) 201 (41) 0.138
Antibody against HCV 3 (21) 128 (26) 0.351
HIV positive 1 (7) 21 (4) 0.751

*Values are no. (%) unless otherwise indicated. ND, not determined; HAV, hepatitis A virus; HBc, hepatitis B core antigen; HCV, hepatitis C virus.
†Totals may not equal 100% because of missing data.

Main Article

TOP